

AFFIDAVIT PURSUANT TO 10 CFR 2.390

I, Mark Johnson, Technical Director of Croft Associates Limited (Croft) hereby affirm and state

1. I have been specifically delegated the function of reviewing the information sought to be withheld and am authorized to apply for its withholding on behalf of Croft.
2. Croft is providing NRC with evidence as part of the SAFKEG-LS 3979A SARP submission Docket No 07109337. This information contains proprietary commercial information both of Croft and also relating to users of the package.
3. The information sought to be withheld pursuant to the provisions of paragraph (a)(4) of 10 CFR 2.390 are the documents listed below, which are marked as follows in the SARP submissions "Proprietary information submitted under 10 CFR 2.390 to be withheld from public disclosure under 10 CFR 2.390".
4. These documents should be held in confidence by the NRC based on paragraph (b)(4) of 10 CFR 2.390 because:
 - i) This information is and has been held in confidence by Croft.
 - ii) This information is of a type that is customarily held in confidence by Croft and there is a rational basis for doing so because this information if released might result in the loss of an existing or potential competitive advantage as follows:
 - a. The information reveals the distinguishing aspects of the design and the prevention of its use by Croft's competitors gives Croft a competitive economic advantage.
 - b. The information, if used by a competitor, is likely to reduce the competitor's expenditure of resources or improve their advantage in the design, quality and manufacture of a similar product.
 - iii) This information is of a type that is customarily held in confidence by users of the package and there is a rational basis for doing so because this information if released might result in the loss of an existing or potential competitive advantage as follows:
 - a. The information reveals the development of radiopharmaceuticals and the prevention of its use by the user's competitors gives the Croft package users a competitive economic advantage.
 - iv) This information is being transmitted to the NRC voluntarily and in confidence.
 - v) This information is not available in public sources.
 - vi) Public disclosure of this information is likely to cause substantial harm to the competitive position of Croft or users of the package because of the reasons outlined below.
 - a. Similar products are manufactured and sold by competitors of Croft.
 - b. Similar radiopharmaceuticals are being developed by competitors of the users of the Croft package.
 - c. The development of this information by Croft is the result of significant expenditure of staff effort and a considerable amount of money. It is my belief that a competitor of Croft or of the package users would have to undertake similar effort and expense to generate equivalent information.

- d. In order to generate such information, a competitor of Croft or of the package users would also require considerable time.
 - e. If a competitor of Croft or of the package users used this information and did not have to undertake the work required to generate this information they are likely to have lower overall costs and so are likely to have an unfair economic advantage over Croft in offering a similar product to the market.
5. Accordingly, Croft requests that the designated information be withheld from public disclosure pursuant to paragraph (a)(4) of CFR 10 2.390.

Documentation to be withheld from public disclosure:

#	Document Reference	Issue	Title	Comments
1	CTR2008-10-Rev11-v1-Safety Analysis Report LS 3979A.pdf	11	Safety Analysis Report for Packaging, Safkeg-LS Design No. 3979A, Package Docket No. 07109337	Including all referenced supporting documentation marked in accordance with 3 above. Redacted copy has been provided (Document reference "CTR2008-10-Rev11-v11-Safety Analysis Report LS 3979A - redacted.pdf") which can be made available for public disclosure.
2	PCS 036-F-d1 SAFKEG-LS Contents	F	Package Contents Specification for SAFKEG-LS Package Design No 3979A	-

Further documents may be provided in addition to this list in support of the NRC review of the request. Where these documents should also be withheld from public disclosure they will be marked as such.

Executed on July 23, 2026

Mark Johnson



Technical Director - Croft Associates Limited
[3979A Affidavit July 2026]